Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit

Vaxxinity COVID-19 Vaccine Plans Hit Roadblock

Executive Summary

Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock.

You may also be interested in...



What’s Next? Five Things To Look Out For In December

As 2021 draws to a close, Coherus BioSciences awaits word on its FDA filing for biosimilar Humira, while Pfizer plots a submission for a designation for interchangeability, aiming to emulate that enjoyed by Boehringer Ingelheim’s Cyltezo. Aurobindo will also plan for the exit of popular managing director Narayanan Govindarajan.

Aurobindo Files First Biosimilar In Europe With Pegfilgrastim

Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.

Indian Companies Find US Partners For COVID-19 Vaccines

Serum Institute has struck a partnership with Dynavax and Aurobindo Pharma with US-based company COVAXX for new vaccine candidates while Bharat Biotech has tied up with Ocugen to explore marketing of its existing contender, Covaxin, in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel